Bernardo L. Rapoport

11.1k total citations · 4 hit papers
199 papers, 6.6k citations indexed

About

Bernardo L. Rapoport is a scholar working on Oncology, Surgery and Physiology. According to data from OpenAlex, Bernardo L. Rapoport has authored 199 papers receiving a total of 6.6k indexed citations (citations by other indexed papers that have themselves been cited), including 116 papers in Oncology, 64 papers in Surgery and 33 papers in Physiology. Recurrent topics in Bernardo L. Rapoport's work include Nausea and vomiting management (57 papers), Cancer Immunotherapy and Biomarkers (46 papers) and Anesthesia and Pain Management (34 papers). Bernardo L. Rapoport is often cited by papers focused on Nausea and vomiting management (57 papers), Cancer Immunotherapy and Biomarkers (46 papers) and Anesthesia and Pain Management (34 papers). Bernardo L. Rapoport collaborates with scholars based in South Africa, United States and Germany. Bernardo L. Rapoport's co-authors include Ronald Anderson, Jørn Herrstedt, Jean Klášterský, Timothy J. Littlewood, J.W.R. Nortier, Els Vercammen, Emilio Bajetta, Matti Aapro, K. V. I. Rolston and Marianne Paesmans and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Bernardo L. Rapoport

182 papers receiving 6.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effects of Epoetin Alfa on Hematologic Parameters and Quality of Life in Cancer Patients Receiving Nonplatinum Chemotherapy: Results of a Randomized, Double-Blind, Placebo-Controlled Trial

2001 792 citations Bernardo L. Rapoport et al. profile →
The Multinational Association for Supportive Care in Cancer Risk Index: A Multinational Scoring System for Identifying Low-Risk Febrile Neutropenic Cancer Patients

2000 768 citations Bernardo L. Rapoport et al. profile →
Management of febrile neutropaenia: ESMO Clinical Practice Guidelines

2016 444 citations Bernardo L. Rapoport, Matti Aapro et al. Annals of Oncology profile →
2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients

2016 397 citations Matti Aapro, Richard J. Gralla et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Bernardo L. Rapoport

Since Specialization

Citations

This map shows the geographic impact of Bernardo L. Rapoport's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bernardo L. Rapoport with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bernardo L. Rapoport more than expected).

Fields of papers citing papers by Bernardo L. Rapoport

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bernardo L. Rapoport. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bernardo L. Rapoport. The network helps show where Bernardo L. Rapoport may publish in the future.

Co-authorship network of co-authors of Bernardo L. Rapoport

This figure shows the co-authorship network connecting the top 25 collaborators of Bernardo L. Rapoport. A scholar is included among the top collaborators of Bernardo L. Rapoport based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bernardo L. Rapoport. Bernardo L. Rapoport is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Current and Emerging Insights into the Causes, Immunopathogenesis, and Treatment of Cutaneous Squamous Cell Carcinoma 2025 ·Cancers ·Ronald Anderson, (unknown), (unknown), Helen C. Steel, Theresa M. Rossouw, Lindsay M. Anderson, Bernardo L. Rapoport	1
2	Immunopathogenesis and Therapeutic Implications in Basal Cell Carcinoma: Current Concepts and Future Directions 2025 ·Medicina ·Helen C. Steel, Theresa M. Rossouw, Ronald Anderson, Lindsay M. Anderson, (unknown), Teresa Smit, Bernardo L. Rapoport	0
3	Filgrastim biosimilar (EP2006): A review of 15 years’ post-approval evidence 2024 ·Critical Reviews in Oncology/Hematology ·Pere Gascón, Nadia Harbeck, Bernardo L. Rapoport, Ronald Anderson, (unknown), Sebastian Howe, Matti Aapro	0
4	Transforming growth factor-β1 and soluble co-inhibitory immune checkpoints as putative drivers of immune suppression in patients with basal cell carcinoma 2024 ·Translational Oncology ·(unknown), (unknown), Helen C. Steel, Pieter Meyer, Teresa Smit, Ronald Anderson, Bernardo L. Rapoport	2
5	Dysregulation of systemic soluble immune checkpoints in early breast cancer is attenuated following administration of neoadjuvant chemotherapy and is associated with recovery of CD27, CD28, CD40, CD80, ICOS and GITR and substantially increased levels of PD-L1, LAG-3 and TIM-3 2023 ·Frontiers in Oncology ·Bernardo L. Rapoport, Helen C. Steel, (unknown), Simon Nayler, Teresa Smit, (unknown), Annette J. Theron, (unknown), (unknown), Pieter Meyer, Ronald Anderson	9
6	2023 updated MASCC/ESMO consensus recommendations: controlling nausea and vomiting with chemotherapy of low or minimal emetic potential 2023 ·Supportive Care in Cancer ·Ian Olver, Rebecca Clark-Snow, Christina H. Ruhlmann, (unknown), Lee S. Schwartzberg, Bernardo L. Rapoport, Franziska Jahn	3
7	Role of Clock Genes and Circadian Rhythm in Renal Cell Carcinoma: Recent Evidence and Therapeutic Consequences 2023 ·Cancers ·Matteo Santoni, Javier Molina‐Cerrillo, Giorgio Santoni, Elaine T. Lam, Francesco Massari, Veronica Mollica, Giulia Mazzaschi, Bernardo L. Rapoport, Enrique Grande, Sebastiano Buti	8
8	Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents—updated MASCC/ESMO consensus recommendation 2023 ·Supportive Care in Cancer ·Karin Jordan, Alexandre Chan, Richard J. Gralla, Franziska Jahn, Bernardo L. Rapoport, Christina H. Ruhlmann, (unknown), Paul J. Hesketh	12
9	Tumor-Infiltrating Lymphocytes (TILs) in Early Breast Cancer Patients: High CD3+, CD8+, and Immunoscore Are Associated with a Pathological Complete Response 2022 ·Cancers ·Bernardo L. Rapoport, Simon Nayler, Bernhard Mlecnik, Teresa Smit, (unknown), (unknown), (unknown), Jérôme Galon, Carol‐Ann Benn, Ronald Anderson	18
10	Frontiers in Pharmacology: Review Manuscript Targeting of the Neutrophil as an Adjunctive Strategy in Non-Small Cell Lung Cancer 2021 ·Frontiers in Pharmacology ·Ronald Anderson, Ada G. Blidner, Bernardo L. Rapoport	10
11	Prognostic Significance of the Neutrophil/Lymphocyte Ratio in Patients undergoing Treatment with Nivolumab for Recurrent Non-Small-Cell Lung Cancer 2020 ·PubMed ·Bernardo L. Rapoport, Annette J. Theron, Daniel Vorobiof, (unknown), (unknown), (unknown), Teresa Smit, (unknown), (unknown), Johann Raats, (unknown), Ronald Anderson	8
12	High Mobility Group Box 1 in Human Cancer 2020 ·Cells ·Bernardo L. Rapoport, Helen C. Steel, Annette J. Theron, (unknown), Teresa Smit, (unknown), Ronald Anderson	49
13	1984P Tumour infiltrating lymphocytes in early breast cancer: High levels of CD3, CD8 cells and Immunoscore® are associated with pathological CR and time to progression in patients undergoing neo-adjuvant chemotherapy 2020 ·Annals of Oncology ·Bernardo L. Rapoport, Jérôme Galon, Simon Nayler, (unknown), (unknown), Bernhard Mlecnik, Carol‐Ann Benn, (unknown), Ronald Anderson	0
14	Lung Cancer in South Africa 2019 ·Journal of Thoracic Oncology ·(unknown), (unknown), (unknown), Simon Nayler, Bernardo L. Rapoport	19
15	Pathological complete response in early breast cancer patients undergoing neoadjuvant chemotherapy: Focus on Ki-67 and molecular subtypes 2019 ·Annals of Oncology ·Bernardo L. Rapoport, (unknown), (unknown), Teresa Smit, Simon Nayler, Carol‐Ann Benn	7
16	Immune related adverse events associated with ipilimumab and nivolumab 2017 ·Annals of Oncology ·Bernardo L. Rapoport, (unknown), Teresa Smit	0
17	Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial 2015 ·Annals of Oncology ·(unknown), Karin Jordan, (unknown), Elber S. Camacho, (unknown), (unknown), (unknown), (unknown), (unknown), Bernardo L. Rapoport	53
18	A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial 2013 ·Trials ·José Baselga, Frederico Costa, Henry Gómez, Clifford A. Hudis, Bernardo L. Rapoport, Henri Roché, Lee S. Schwartzberg, Oana Petrenciuc, Minghua Shan, William J. Gradishar	31
19	Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement 2004 ·Supportive Care in Cancer ·Lawrence H. Einhorn, Bernardo L. Rapoport, Jim M. Koeller, Steven M. Grunberg, Petra Feyer, Cynthia N. Rittenberg, Matti Aapro	26
20	Repeated use of granisetron in patients receiving cytostatic agents 1993 ·Cancer ·(unknown), Geoffrey Falkson, Bernardo L. Rapoport	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact